Peripheral cholinergic disturbances in Alzheimer's disease

被引:25
|
作者
Rakonczay, Z [1 ]
Horváth, Z
Juhász, A
Kálmán, J
机构
[1] Univ Szeged, Alzheimers Dis Res Ctr, Dept Oral Biol, Szeged, Hungary
[2] Univ Szeged, Fac Med, Dept Psychiat, H-6720 Szeged, Hungary
关键词
Alzheimer's disease; acetylcholinesterase; butyrylcholinesterase; molecular forms; apolipoprotein E; butyrylcholinesterase K variant;
D O I
10.1016/j.cbi.2005.10.034
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The most pronounced neurochemical abnormality in Alzheimer's disease (AD) is cholinergic dysfunction in the central nervous system. Peripheral tissues may also be affected, however, including blood. The present study undertook to determine the activity of acetylcholinesterase (AChE) and its molecular forms in erythrocytes, lymphocytes and platelets of normal elderly subjects and probable AD cases. These samples contained dimeric globular (G2), tetrameric globular (G4) and asymmetric (A12) AChE forms, but no globular monomeric (G1) enzyme. In both lymphocytes and platelets, the major AChE molecular form was G2 (approximately 80%), with G4 and A12 forms accounting for nearly equal portions of the remainder. Total AChE activities and measured sedimentation coefficients were similar in the control and AD samples (from patients with mild and moderately severe cognitive deficiency). However, the groups differed significantly in the proportion of certain AChE molecular forms. Thus, as compared with controls, the amount of A 12 AChE in the AD samples was increased 148 and 161% in lymphocytes and platelets, respectively. Genotyping for apolipoprotein E (ApoE) and the butyrylcholinesterase K (BCHE-K) variant, carried out using the polymerase chain reaction, showed that AD patients carried the ApoE4 allele at a significantly higher frequency than the controls. On the other hand there were no significant group differences in the occurrence of the BCHE-K variant and no synergism between ApoE alleles and the BCHE-K variant in our Hungarian AD population. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:233 / 238
页数:6
相关论文
共 50 条
  • [31] Alzheimer's disease and sleep disturbances: a review
    Borges, Conrad Regis
    Poyares, Dalva
    Piovezan, Ronald
    Nitrini, Ricardo
    Brucki, Sonia
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2019, 77 (11) : 815 - 824
  • [32] Melatonin and Sleep Disturbances in Alzheimer's Disease
    Prodhan, A. H. M. Safayet Ullah
    Cavestro, Cinzia
    Kamal, Mohammad Amjad
    Islam, Mohammad Asiful
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2021, 20 (08) : 736 - 754
  • [33] Sleep rhythm disturbances in Alzheimer's disease
    Onen, F
    Onen, SH
    REVUE DE MEDECINE INTERNE, 2003, 24 (03): : 165 - 171
  • [34] Pharmacotherapies for sleep disturbances in Alzheimer's disease
    McCleery, Jenny
    Cohen, Daniel A.
    Sharpley, Ann L.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (03):
  • [35] Peripheral Biomarkers of Alzheimer's Disease
    Khan, Tapan K.
    Alkon, Daniel L.
    JOURNAL OF ALZHEIMERS DISEASE, 2015, 44 (03) : 729 - 744
  • [36] Peripheral markers of Alzheimer’s disease
    J. P. Blassa
    G. E. Gibson
    K- F. R. Sheu
    Aging Clinical and Experimental Research, 1997, 9 (Suppl 4) : 55 - 56
  • [37] Neuropsychiatric symptoms and cholinergic therapy for Alzheimer's disease
    Levy, ML
    Cummings, JL
    Kahn-Rose, R
    GERONTOLOGY, 1999, 45 : 15 - 22
  • [38] Butyrylcholinesterase: a target in the cholinergic treatment of Alzheimer's disease
    Potkin, SG
    PRIMARY CARE PSYCHIATRY, 2004, 9 (03): : 83 - 87
  • [39] The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease
    Cummings, JL
    Back, C
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 1998, 6 (02): : S64 - S78
  • [40] Optimal use of cholinergic drugs in Alzheimer's disease
    Gauthier, Serge
    Herrmann, Nathan
    Rosa-Neto, Pedro
    BRAIN, 2018, 141